{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:32:55Z","timestamp":1791113575785,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1681,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1038\/ki.2011.48","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T09:40:56Z","timestamp":1300268456000},"page":"1051-1060","source":"Crossref","is-referenced-by-count":132,"title":["Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease"],"prefix":"10.1016","volume":"79","author":[{"given":"Jean-Philippe","family":"Bertocchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2011.48_bb0010","first-page":"3","article-title":"Presidential address I.Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2011.48_bb0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary Aldosteronism from an analysis of 145 Cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"key":"10.1038\/ki.2011.48_bb0020","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2011.48_bb0025","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0035","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0045","first-page":"S49","article-title":"Regulation of sodium transport by steroid hormones","volume":"65","author":"Bonvalet","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2011.48_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1038\/ki.2011.48_bb0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.48_bb0060","doi-asserted-by":"crossref","first-page":"e012","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"10.1038\/ki.2011.48_bb0065","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"10.1038\/ki.2011.48_bb0075","doi-asserted-by":"crossref","first-page":"F593","DOI":"10.1152\/ajprenal.00454.2003","article-title":"Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule","volume":"287","author":"Meneton","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0080","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J"},{"key":"10.1038\/ki.2011.48_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00129784-200707030-00001","article-title":"The role of aldosterone and mineralocorticoid receptors in cardiovascular disease","volume":"7","author":"Funder","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1038\/ki.2011.48_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?","volume":"458","author":"Gekle","year":"2009","journal-title":"Pflugers Arch"},{"key":"10.1038\/ki.2011.48_bb0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/01.HYP.26.6.971","article-title":"Biological determinants of aldosterone-induced cardiac fibrosis in rats","volume":"26","author":"Robert","year":"1995","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0100","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2011.48_bb0105","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.107.098012","article-title":"Mineralocorticoid receptor activation and oxidative stress","volume":"50","author":"Funder","year":"2007","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0110","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1038\/ki.2011.48_bb0115","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2353\/ajpath.2010.090578","article-title":"eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists","volume":"176","author":"Kosugi","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1038\/ki.2011.48_rf0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1038\/ki.2011.48_bb0125","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"10.1038\/ki.2011.48_bb0130","doi-asserted-by":"crossref","first-page":"R946","DOI":"10.1152\/ajpregu.00402.2006","article-title":"Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker","volume":"292","author":"Ohtani","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1038\/ki.2011.48_bb0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats","volume":"47","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1291\/hypres.30.427","article-title":"Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts","volume":"30","author":"Takeda","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1038\/ki.2011.48_bb0145","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.lfs.2005.12.011","article-title":"Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats","volume":"78","author":"de Resende","year":"2006","journal-title":"Life Sci"},{"key":"10.1038\/ki.2011.48_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/10739680490266207","article-title":"Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat","volume":"11","author":"DeLano","year":"2004","journal-title":"Microcirculation"},{"key":"10.1038\/ki.2011.48_bb0155","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/HYPERTENSIONAHA.109.148783","volume":"55","author":"Krug","year":"2010","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0160","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.109.134130","article-title":"Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats","volume":"54","author":"Tada","year":"2009","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0165","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/en.2007-0864","article-title":"Aldosterone induces superoxide generation via Rac1 activation in endothelial cells","volume":"149","author":"Iwashima","year":"2008","journal-title":"Endocrinology"},{"key":"10.1038\/ki.2011.48_bb0170","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/ki.2011.48_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0079-6123(08)81009-6","article-title":"Modulation of steroid hormone receptor activity","volume":"181","author":"Stanisic","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1038\/ki.2011.48_bb0180","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","article-title":"Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling","volume":"52","author":"Di Zhang","year":"2008","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0185","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1161\/HYPERTENSIONAHA.108.121269","article-title":"Networking between systemic angiotensin II and cardiac mineralocorticoid receptors","volume":"52","author":"Montezano","year":"2008","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0190","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2215\/CJN.01340209","article-title":"Mineralocorticoid receptor blockers and chronic kidney disease","volume":"4","author":"Jain","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneph.2010.52","article-title":"Hyperkalemia: a threat to RAAS inhibition?","volume":"6","author":"Schrier","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1038\/ki.2011.48_bb0200","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1210\/en.2005-0860","article-title":"Development of a panel of monoclonal antibodies against the mineralocorticoid receptor","volume":"147","author":"Gomez-Sanchez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1038\/ki.2011.48_bb0205","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0210","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","article-title":"Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts","volume":"46","author":"Nagai","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0215","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions","volume":"297","author":"Lee","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0220","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1681\/ASN.2006080944","article-title":"Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors","volume":"17","author":"Nagase","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0225","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1038\/ki.2011.48_bb0230","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1038\/ki.2011.48_bb0235","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.HYP.0000157408.43807.5a","article-title":"Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway","volume":"45","author":"Kobayashi","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0240","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.1152\/ajpendo.00512.2007","article-title":"Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats","volume":"295","author":"Chun","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1038\/ki.2011.48_bb0245","doi-asserted-by":"crossref","first-page":"F1013","DOI":"10.1152\/ajprenal.90646.2008","article-title":"Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat","volume":"296","author":"Whaley-Connell","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0250","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0255","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1097\/01.ASN.0000078960.15147.05","article-title":"Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP","volume":"14","author":"Chander","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0260","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","article-title":"Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level","volume":"41","author":"Quan","year":"1992","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0265","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0270","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/08860220600779033","article-title":"Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well","volume":"28","author":"Gullulu","year":"2006","journal-title":"Ren Fail"},{"key":"10.1038\/ki.2011.48_bb0275","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00524.2007","article-title":"Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome","volume":"294","author":"Nakhoul","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0280","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2353","article-title":"The role of aldosterone blockade in murine lupus nephritis","volume":"10","author":"Monrad","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1038\/ki.2011.48_bb0285","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1681\/ASN.2005121375","article-title":"Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury","volume":"17","author":"Sun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0290","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3317\/jraas.2007.014","article-title":"Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats","volume":"8","author":"Yuan","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1038\/ki.2011.48_bb0300","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0305","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0310","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0315","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","article-title":"New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone","volume":"293","author":"Bobadilla","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0320","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1681\/ASN.2005090955","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation","volume":"17","author":"Heinze","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0325","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0002-9343(87)90497-9","article-title":"Suppression of plasma renin activity by cyclosporine","volume":"83","author":"Bantle","year":"1987","journal-title":"Am J Med"},{"key":"10.1038\/ki.2011.48_bb0330","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1389200023337964","article-title":"Interaction of cyclosporine A and the renin-angiotensin system; new perspectives","volume":"3","author":"Lassila","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1038\/ki.2011.48_bb0335","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity","volume":"289","author":"Perez-Rojas","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0340","doi-asserted-by":"crossref","first-page":"F131","DOI":"10.1152\/ajprenal.00147.2006","article-title":"Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity","volume":"292","author":"Perez-Rojas","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0350","doi-asserted-by":"crossref","first-page":"F1072","DOI":"10.1152\/ajprenal.90643.2008","article-title":"Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats","volume":"296","author":"Waanders","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2011.48_bb0355","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/ndt\/gfn204","article-title":"Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats","volume":"23","author":"Nielsen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.48_bb0360","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \u2018Gruppo Italiano di Studi Epidemiologici in Nefrologia\u2019 (GISEN)","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0365","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u2018Escape\u2019 of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1038\/ki.2011.48_rf0370","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2011.48_bb0375","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1038\/ki.2011.48_bb0380","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0385","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00467-009-1176-z","article-title":"Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children","volume":"24","author":"Ku","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2011.48_bb0390","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1172\/JCI119249","article-title":"Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion","volume":"99","author":"Okubo","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2011.48_bb0395","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2010","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2011.48_bb0400","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","article-title":"Control of aldosterone secretion: a model for convergence in cellular signaling pathways","volume":"84","author":"Sp\u00e4t","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1038\/ki.2011.48_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.48_bb0415","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0420","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0425","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJM200202073460619","article-title":"Spironolactone and ACE inhibition in chronic renal failure","volume":"346","author":"Epstein","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0430","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0435","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1038\/ki.2011.48_bb0440","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0445","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0450","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1038\/ki.2011.48_bb0455","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.48_bb0460","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1038\/ki.2011.48_bb0465","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0470","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0475","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1038\/ki.2011.48_bb0480","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1210\/jc.2005-1718","article-title":"Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy","volume":"91","author":"Takebayashi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2011.48_bb0485","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.48_bb0490","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.48_bb0495","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2010.46","volume":"33","author":"Ando","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1038\/ki.2011.48_bb0500","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-9343(03)00293-6","article-title":"Aldosterone blockade and vascular calcification in hemodialysis patients","volume":"115","author":"Nitta","year":"2003","journal-title":"Am J Med"},{"key":"10.1038\/ki.2011.48_bb0505","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.48_bb0510","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0515","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic haemodialysis patients","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.48_bb0520","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/ndt\/gfg413","article-title":"Is spironolactone safe for dialysis patients?","volume":"18","author":"Hussain","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.48_bb0525","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0530","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1523-1755.2004.00931.x","article-title":"Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients","volume":"66","author":"Michea","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.48_bb0535","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000210553","article-title":"Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients","volume":"114","author":"Matsumoto","year":"2009","journal-title":"Cardiology"},{"key":"10.1038\/ki.2011.48_bb0540","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/17.11.2035","article-title":"Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function","volume":"17","author":"Hausmann","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.48_bb0545","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?","volume":"33","author":"Chua","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1038\/ki.2011.48_bb0550","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00467-006-0270-8","article-title":"The effect of aldosterone blockade in patients with Alport syndrome","volume":"21","author":"Kaito","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2011.48_bb0555","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1345\/aph.1E618","article-title":"Clinical experience with spironolactone in pediatrics","volume":"39","author":"Buck","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1038\/ki.2011.48_bb0560","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.48_bb0565","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000245635","article-title":"Aldosterone in uremia\u2014beyond blood pressure","volume":"29","author":"Ritz","year":"2010","journal-title":"Blood Purif"},{"key":"10.1038\/ki.2011.48_bb0570","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"10.1038\/ki.2011.48_bb0575","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cardfail.2006.01.003","article-title":"Appropriateness of spironolactone prescribing in heart failure patients: a population-based study","volume":"12","author":"Ko","year":"2006","journal-title":"J Card Fail"},{"key":"10.1038\/ki.2011.48_bb0580","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/ndt\/gfg339","article-title":"Aldosterone receptor blockade and the role of eplerenone: evolving perspectives","volume":"18","author":"Epstein","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.48_bb0585","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/hr.2010.71","article-title":"Eplerenone in chronic renal disease: the EVALUATE trial","volume":"33","author":"Funder","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1038\/ki.2011.48_bb0590","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.48_bb0595","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2011.48_bb0600","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381554711X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381554711X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T04:33:34Z","timestamp":1560054814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381554711X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S008525381554711X"],"URL":"https:\/\/doi.org\/10.1038\/ki.2011.48","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}